Cerevel Therapeutics Holdings, Inc.

Cerevel did not report revenue or EPS on the call. Third-quarter 2023 operating expenses were approximately $111 million, including $85 million of R&D expense and $26 million of G&A expense. In October, the company completed a $499 million capital raise, and ended Q3 with roughly $758 million in cash, cash equivalents and marketable securities. Management said this capital, combined with the quarter-end cash balance, supports operations into 2026. Forward-looking guidance centered on multiple 2024 readouts: emraclidine EMPOWER-1 and EMPOWER-2 in 2H24, tavapadon TEMPO-3 in 1H24 and TEMPO-1/TEMPO-2 in 2H24, and darigabat’s realized focal epilepsy readout in mid-2024. The company also said it is preparing for two potential NDA filings in 2025 for tavapadon and emraclidine if data are positive.

Ron Renaud framed 2024 as a pivotal year, saying Cerevel has one of the most robust neuroscience pipelines and that multiple mid- and late-stage readouts are coming across three assets and three indications. He emphasized execution, saying the team is focused on delivering high-quality data, preparing for two potential NDA filings, and exploring lifecycle opportunities for lead programs and additional indications. His tone was confident and upbeat, but he repeatedly tied that optimism to disciplined execution and data quality.

Susan Altschuller highlighted the October $499 million capital raise and said quarter-end cash, cash equivalents and marketable securities were roughly $758 million, which she said supports operations into 2026. She also reported Q3 operating expenses of about $111 million, split between $85 million of R&D and $26 million of G&A. Her message was that the stronger balance sheet gives the company optionality, while spending will remain disciplined as it advances lead assets and prepares for two potential NDA filings in parallel.

Analysts repeatedly focused on emraclidine enrollment quality and placebo-response risk, especially after a recent competitor setback, and management said it is using site visits, frequent rater recertification, stricter patient selection and a limited number of countries/sites to improve enrollment without sacrificing data quality. Questions also centered on darigabat’s epilepsy readout and slow enrollment; management said the issue was finding the right patient profile because concomitant anti-epileptics are 3A4 inducers, and it is mitigating this with more sites/countries and a drug-drug interaction study to support later development. On tavapadon, management said it sees a clear clinical role as both monotherapy and adjunctive therapy and confirmed the NDA would include all three Phase 3 trials plus the open-label extension.